• The recommended dosage is 10 mg, 30 mg, or 60 mg taken orally once daily with or without food.
• Severe Renal Impairment or End-Stage Renal Disease: 10 mg once daily.
Most viewed Qulipta resources
Enroll in Patient Savings Program
drug label
Qulipta prescribing information
Have more Qulipta questions?
Submit MSL Request
Learn More
Your request will be referred to the appropriate AbbVie Inc. medical professional, such as a Qulipta pharmaceutical rep; Medical Science Liaison (MSL) or medical affairs.
Need to report a Qulipta issue?
ONLINE FORMReport adverse event
Learn More
You can report a Qulipta adverse event on MedWatch, the FDA's medical product safety reporting program for health professionals, patients and consumers.
samples
Request Qulipta samples
Sample Online Form
Learn More
Is my patient elegible for Qulipta samples?
Your rep will communicate with you how to receive samples, when you can receive samples, the amount and more.
How do I find out who my Qulipta rep is?
Not sure who your local Qulipta pharma rep is? Reach out to AbbVie Inc. and they can help you identify your rep.
prior authorization
Qulipta Prior authorization resources
Complete Letter of Medical Necessity
NOT PROVIDED BY BRANDComplete Coverage Authorization request
If available, these templates are provided by the brand to help you navigate insurance, especially with newer drugs.
Benefits investigation
Qulipta Complete Enrollment Form
Learn More
Benefits investigations are conducted to determine whether a therapy is covered under a patient's insurance, if a prior authorization is required, and which specialty pharmacies are preferred.
Reimbursement help (FRM)
NOT PROVIDED BY BRANDReimbursement help (FRM) resources
Learn More
Some brands offer a field reimbursement manager who will work with your clinical staff and preferred pharmacy to help make sure patients don't fall through the cracks.
financial assistance
Qulipta Financial assistance options
Co-pay savings program
commercial only
Qulipta Complete Enrollment Form
Enroll in Patient Savings Program
Learn More
Overview
Reduce patient OOP costs for drug (and occasionally for drug administration/infusion costs or drug-related test costs)
Patient benefit
A portion (or all) of patient OOP (deductible, copay), typically up to monthly and/or annual max
Patient eligibility
Patient must enroll or activate (may permit HCPs to enroll on patient’s behalf for HCP-administered drugs)
Generally, must have commercial insurance (rarely, may permit uninsured patients to use)
May never be used with government insurance
How to sign up
Cards may be downloadable digital cards or hard copies
Some pharmacos offer debit cards with pre-loaded copay benefit
Typically, available through multiple channels (e.g., rep to HCP to patient; pharmacy to patient; patient via website, Hub live agent, or copay vendor (live agent or IVR); patient and HCP via Hub enrollment form)
Some HCP-administered product programs permit HCPs to enroll on a patient’s behalf through via Hub form
Bridge program
commercial only
Qulipta Complete Enrollment Form
Learn More
Overview
Provide patient immediate access to therapy during an insurance delay (typically new starts; some may cover change in insurance)
Limited time/ fill (typically 7-30 days; some may offer additional fill for continued delay up to certain limit)
Patient benefit
100% free (outside of insurance)
Patient eligibility
HCP must enroll patient
May be limited to commercially insured patients (i.e., no government beneficiaries); some programs may allow government beneficiaries
How to sign up
Typically HCP assisted enrollment (via form)
Foundation programs
under insured
no insurance
goverment insurance
65+
Abbvie Assist Patient Assistance Program Application - English
Abbvie Assist Patient Assistance Program Application - Spanish
Learn More
Overview
Charitable 501(c)(3) organizations provide direct cost-sharing and other support (e.g., travel, counseling) through disease-state funds to indigent patients on first-come first-served basis
These organizations may receive financial contributions from drug manaufacturers for particular disease-state funds that cannot provide funds directly to patients - the foundation must be independent/unaligned
Patient benefit
Patients apply for grants that cover a portion (or all) of their out-of-pocket costs (deductibles and co-pays) until the grant is exhausted
Patient eligibility
Patients must apply and meet eligibility criteria including income level (typically a multiple of federal poverty line), specific diagnosis, insurance status, etc.
How to sign up
Patients submit proof of out-of-pocket drug costs to charities for reimbursement
patient education
Qulipta Patient education
Getting started on Qulipta
NOT PROVIDED BY BRANDInstructions For Use - Migraine Prevention
Patient toolkit
About Qulipta
ASK PATIENT TO: Open Camera on Phone Scan QR Code & Tap Link
Patient Brochure
ASK PATIENT TO: Open Camera on Phone Scan QR Code & Tap Link
Learn More
Other resources brands publish to help support patients and caregivers.
people also ask
Qulipta FAQs
Is QULIPTA safe to use during pregnancy?There are no adequate data on the developmental risk associated with the use of QULIPTA in pregnant women. In animal studies, oral administration of atogepant during the period of organogenesis (rats and rabbits) or throughout pregnancy and lactation (rats) resulted in adverse developmental effects (decreased fetal and offspring body weight in rats; increased incidence of fetal structural variations in rabbits) at exposures greater than those used clinically. Women who are pregnant or planning to become pregnant should consult with their healthcare provider to determine the best treatment option for their migraine.
Is QULIPTA safe to use during lactation?There are no data on the presence of atogepant in human milk, the effects of atogepant on the breastfed infant, or the effects of atogepant on milk production. In lactating rats, oral dosing with atogepant resulted in levels of atogepant in milk approximately 2-fold higher than that in maternal plasma. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for QULIPTA and any potential adverse effects on the breastfed infant from QULIPTA or from the underlying maternal condition.
Is QULIPTA safe to use in pediatric patients?Safety and effectiveness in pediatric patients have not been established. QULIPTA is not recommended for use in pediatric patients.
Is QULIPTA safe to use in elderly patients?Population pharmacokinetic modeling suggests no clinically significant pharmacokinetic differences between elderly and younger subjects. Clinical studies of QULIPTA did not include sufficient numbers of patients aged 65 years and over to determine whether they respond differently from younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
Is QULIPTA safe to use in patients with hepatic impairment?No dose adjustment of QULIPTA is recommended for patients with mild or moderate hepatic impairment. Avoid use of QULIPTA in patients with severe hepatic impairment.
Is QULIPTA safe to use in patients with renal impairment?The renal route of elimination plays a minor role in the clearance of atogepant. No dose adjustment is recommended for patients with mild or moderate renal impairment.
FAQ Data Source
We receive information directly from the FDA and PrescriberPoint is updated as frequently as change are made available
Can't find what you're looking for?
Our trained staff can help you:
Please note:
Access to a Field Reimbursement Manager (FRM) or Medical Science Liaison (MSL) varies by brand and may require talking with your rep first.
Samples are provided at the discretion of the brand.
We are unable to collect Protected Health Information (PHI), fill out forms, or submit them on your behalf.